Who is sponsoring NCT02010645?

NCT02010645 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02010645?

Interventions: Eltrombopag, Decitabine.

What is the status of NCT02010645?

NCT02010645 is currently TERMINATED.

Last reviewed 2019-12-13 · How we verify

Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome

NCT02010645 Phase 2 TERMINATED Results posted

The goal of this clinical research study is to learn if eltrombopag given in combination with decitabine can help to control advanced MDS. The safety of this study drug combination will also be studied.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	TERMINATED
Enrolment	6
Start date	2014-03
Completion	2019-01-02

Conditions

Leukemia

Interventions

Eltrombopag
Decitabine

Primary outcomes

Overall Response Rate (ORR) — 28 days
The primary endpoint is the overall response rate (ORR) based on the IWG-2006 criteria, which includes complete remission (CR), partial remission (PR), and hematologic improvement (HI).

Countries

United States